View Older Stories

Oct 5, 2026 06:24AM Genmab A/S (GMAB) PT Raised to $54 at Guggenheim

Oct 5, 2026 06:19AM Leerink Resumes Genmab A/S (GMAB) at Outperform

Sep 14, 2026 07:33AM H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

Aug 6, 2026 11:02AM Genmab revenue rises 25% in first half of 2026, guidance raised

Jul 22, 2026 06:16AM TD Cowen Upgrades Genmab A/S (GMAB) to Buy

Jul 15, 2026 06:23AM Darzalex global sales reach $4.2 billion in Q2 2026

Jul 13, 2026 06:36AM H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

Jul 6, 2026 01:45PM EU approves Genmab's Tepkinly combo for relapsed follicular lymphoma

Jul 2, 2026 06:41AM Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright

Jul 1, 2026 06:19AM William Blair Adjusts Monthly Analyst Conviction List for July 2026

Jun 11, 2026 10:46AM Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment

May 27, 2026 06:09AM Truist Securities Assumes Genmab A/S (GMAB) at Buy

Apr 30, 2026 06:52AM Genmab A/S (GMAB) PT Lowered to $38 at H.C. Wainwright

Apr 22, 2026 12:56AM Goldman Sachs Upgrades Genmab A/S (GEN:DC) (GMAB) to Buy

Apr 21, 2026 03:12PM Genmab A/S (GMAB) April 30, 35 and 40 calls active, share price down 2.5%

Apr 17, 2026 10:58AM Genmab reduces share capital by DKK 1.9 million through cancellation

Apr 14, 2026 06:23AM Genmab reports $3.96 billion in DARZALEX sales for first quarter 2026

Apr 13, 2026 09:36AM Genmab shows safety data for ovarian cancer drug combination

Mar 26, 2026 04:09PM Wolfe Research Starts Genmab A/S (GMAB) at Outperform

Mar 19, 2026 02:22PM Genmab names new board leadership, grants employee equity awards

Mar 2, 2026 06:08AM Wells Fargo Starts Genmab A/S (GMAB) at Overweight

Feb 23, 2026 06:28AM Genmab A/S (GMAB) PT Lowered to $40 at Guggenheim

Feb 21, 2026 04:00PM Jefferies sees a 'catalyst-rich' path for this pharma stock

Feb 18, 2026 07:29AM Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright

Feb 18, 2026 03:49AM Genmab A/S (GMAB) Reports FY EPS of $15.37

Feb 17, 2026 03:18PM Genmab initiates share buyback program worth up to 725 million DKK

Feb 17, 2026 04:23AM Jefferies Resumes Genmab A/S (GEN:DC) (GMAB) at Buy

Jan 28, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

Jan 21, 2026 06:24AM Genmab reports $14.35 billion in DARZALEX sales for 2025

Jan 20, 2026 06:39AM Genmab A/S (GMAB) PT Lowered to $39 at H.C. Wainwright

Jan 16, 2026 01:52PM Genmab A/S (GMAB) resumes trading

Jan 16, 2026 12:59PM Genmab A/S (GMAB) halted, news pending

Jan 8, 2026 02:49AM Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,750 at UBS

Jan 7, 2026 09:02AM Genmab partners with Anthropic to deploy AI for drug development

Dec 29, 2025 08:11AM Genmab discontinues acasunlimab development to focus on late-stage programs

Dec 8, 2025 04:15AM Genmab A/S (GMAB) PT Raised to $38 at Leerink Partners

Dec 1, 2025 05:30PM This pharma stock has 3 'material catalysts' in 2026: BofA

Nov 18, 2025 11:30AM Genmab receives FDA approval for EPKINLY combination in follicular lymphoma

Nov 10, 2025 06:48AM Genmab A/S (GMAB) PT Raised to $41 at H.C. Wainwright

Nov 6, 2025 03:03PM Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities

Oct 27, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

Oct 21, 2025 08:13AM Genmab launches $97 per share tender offer for Merus

Oct 21, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

Oct 14, 2025 06:23AM Genmab reports DARZALEX net sales of $3.67 billion in Q3 2025

Oct 13, 2025 04:48AM Genmab A/S (GMAB) PT Raised to $39 at Leerink Partners

Oct 6, 2025 08:44AM Genmab A/S (GMAB) PT Raised to $49 at Truist Post MRUS Acquisition

Oct 3, 2025 07:53AM Genmab A/S (GMAB) PT Raised to $49 at Truist Securities

Oct 3, 2025 06:41AM Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright

Sep 30, 2025 08:25AM Truist Reiterates Buy Rating on Genmab A/S (GMAB) Following MRUS Bid

Sep 30, 2025 04:26AM Genmab A/S (GMAB) PT Raised to $32 at TD Cowen

View Older Stories